Phenomix is a drug discovery and development company building a portfolio of novel therapeutics for the treatment of major human diseases.
As of October 2010, Phenomix closed down as it was unable to find a partner to pay for is clinical trial bills after Forest Laboratories walked away. Phenomix is a drug discovery and development company building a portfolio of novel therapeutics for the treatment of major human diseases. Phenomix' lead clinical candidate, PHX1149, is a DPP4 inhibitor in phase 2 testing as a once daily oral treatment for type 2 diabetes. Phenomix' second program is directed at the treatment of hepatitis C through inhibition of the NS3/4A viral protease. Phenomix is based in San Diego, California.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Mar 8, 2007 | Series C | $55M | 1 | Phase4 Ventures | — | Detail |
Mar 11, 2002 | Series A | $12M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Phase4 Ventures | Yes | Series C |
Versant Ventures | — | Series A |